ESGBIS publishes study on predictive score for BSI outcome in JAC
Bloodstream infections (BSIs) due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae (ESBL-E) are frequent, but outcome prediction rules for clinical use have not been developed. An international group of researchers supported by ESCMID’s study group for BSIs defined and validated an easy-to-collect predictive scoring model for all-cause 30-day mortality useful for identifying patients at high and low risk of mortality. The study was published in the Journal of Antimicrobial Chemotherapy.
CMI highlight: narrow-spectrum beta-lactam monotherapy in pneumonia
Researchers in Sweden assessed the clinical effect of empirical treatment with narrow-spectrum beta-lactam monotherapy (NSBM) versus broad-spectrum beta-lactam monotherapy (BSBM) in non-severe community-acquired pneumonia (CAP). They observed no significant differences in 30-day and 90-day mortality between NSBM and BSBM. Patients who received BSBM were more often treated in an intensive care unit and had longer length of stay. Empirical NSBM appears to be effective in the majority of hospitalized immunocompetent adults with non-severe CAP and should be further evaluated in randomized trials, the authors concluded.
This postgraduate education course from 28 – 31 March targets 20 to 60 microbiologists and infectious disease specialists who want updated knowledge of the theoretical and practical aspects of current and advanced diagnosis and management of bloodstream infection (BSI). Speakers will present advanced technologies to improve disease management in a context of challenges including multi-drug resistant pathogens as well as new approaches including molecular detection tools or biofilm or anti-infective lock therapy in catheter-associated BSI. Find out more about the programme, grant application and registration timelines.
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.
Tip: To ensure that you receive the ESCMID newsletter in your inbox, add email@example.com to your email program’s address book.
You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.